Cyclooxygenase–2 Promotes Hepatocellular Carcinoma Cell Growth Through Akt Activation: Evidence for Akt Inhibition in Celecoxib–Induced Apoptosis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Cyclooxygenase–2 (COX–2)–controlled prostaglandin (PG) metabolism recently has been implicated in the pathogenesis of hepatocellular carcinoma (HCC). However, the biologic role and molecular mechanism of COX–2–mediated PGs in the control of liver cancer growth have not been established. This study was designed to examine the direct effect of COX–2 and its inhibitor celecoxib on the growth control of liver cancer cells. Human HCC cell lines Hep3B and HepG2 transfected with COX–2 expression vector showed increased cell growth and enhanced phosphorylation of serine/threonine protein kinase B (Akt). The level of COX–2 expression and Akt phosphorylation is correlated positively in cultured HCC cells and human liver cancer tissues. Inhibition of Akt activation by phosphatidylinositol 3–kinase (PI3–kinase) inhibitor LY294002 significantly decreased the viability of Hep3B and HepG2 cells (P < .01). These results reveal a novel role of Akt activation in COX–2–induced HCC cell survival. Furthermore, HCC cells treated with the COX–2 inhibitor celecoxib showed significant reduction of Akt phosphorylation and marked morphologic and biochemical characteristics of apoptosis. Overexpression of COX–2 or addition of exogenous PGE 2 partially prevented celecoxib–induced apoptosis (P < .01). In conclusion, our results suggest the involvement of COX–2–dependent and –independent mechanisms in celecoxib–mediated HCC cell apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
(2012) · Hepatogastroenterology · doi:10.5754/hge12183 · Cited by 1,625
The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998) · Nature · doi:10.1038/23948 · Cited by 1,590
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & Dubois, R. N. (1998) · PubMed · Cited by 1,246
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., & Evan, G. (1997) · Nature · doi:10.1038/385544a0 · Cited by 1,148
Cited by
Global Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.001 · Cited by 908
Su, H., Yang, J.-R., Xu, T., Huang, J., Xu, L., Yuan, Y., & Zhuang, S.-M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2886 · Cited by 612
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., Zazzeroni, F., & Alesse, E. (2013) · BioMed Research International · doi:10.1155/2013/187204 · Cited by 408
Obesity and hepatocellular carcinoma
Caldwell, S. H., Crespo, D. M., Kang, H. S., & Al-Osaimi, A. M. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.021 · Cited by 396
Inflammation and Liver Cancer: New Molecular Links
Berasain, C., Castillo, J., Perugorria, M. J., Latasa, M. U., Prieto, J., & Avila, M. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03704.x · Cited by 390
Yang, L.-Y., Luo, Q., Lu, L., Zhu, W.-W., Sun, H.-T., Wei, R., Lin, Z.-F., Wang, X.-Y., Wang, C.-Q., Lu, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0836-0 · Cited by 370
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Simon, T. G., Duberg, A.-S., Aleman, S., Chung, R. T., Chan, A. T., & Ludvigsson, J. F. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912035 · Cited by 304
Dysregulation of apoptosis in hepatocellular carcinoma cells
Fabregat, I. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.513 · Cited by 280
Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells
Liu, X., Yue, P., Zhou, Z., Khuri, F. R., & Sun, S.-Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh322 · Cited by 265
Hung, J.-H., Su, I.-J., Lei, H.-Y., Wang, H.-C., Lin, W.-C., Chang, W.-T., Huang, W., Chang, W.-C., Chang, Y.-S., Chen, C.-C., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403568200 · Cited by 257
PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019) · Cancers · doi:10.3390/cancers11081076 · Cited by 189
Choudhari, S. R., Khan, M. A., Harris, G., Picker, D., Jacob, G. S., Block, T., & Shailubhai, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0561 · Cited by 90
Metadata
- Authors
- Leng, J., Han, C., Demetris, J. A., Michalopoulos, G. K., & Wu, T.
- Venue
- Hepatology
- Published
- 2003-09
- Volume
- 38
- Issue
- 3
- Pages
- 756-768
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1996785337
- Cited by
- 258
- References
- 45
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.